Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
AstraZeneca
Johnson and Johnson
Cipla
Healthtrust
US Army
UBS
Cerilliant
McKesson

Generated: February 17, 2019

DrugPatentWatch Database Preview

Zydus Pharms Usa Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ZYDUS PHARMS USA INC, and when can generic versions of ZYDUS PHARMS USA INC drugs launch?

ZYDUS PHARMS USA INC has one hundred and seventy-one approved drugs.

There is one US patent protecting ZYDUS PHARMS USA INC drugs. There are eight tentative approvals on ZYDUS PHARMS USA INC drugs.

There are two patent family members on ZYDUS PHARMS USA INC drugs in two countries and two hundred and twenty-five supplementary protection certificates in twelve countries.

Summary for Zydus Pharms Usa Inc
International Patents:2
US Patents:1
Tradenames:145
Ingredients:144
NDAs:171

Drugs and US Patents for Zydus Pharms Usa Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc ETODOLAC etodolac TABLET, EXTENDED RELEASE;ORAL 091134-001 Jan 23, 2014 AB RX No No ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc TOPIRAMATE topiramate TABLET;ORAL 078235-003 Mar 27, 2009 AB RX No No ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc DOXYCYCLINE doxycycline TABLET;ORAL 209582-004 Sep 28, 2017 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ZYDUS PHARMS USA INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03

Supplementary Protection Certificates for Zydus Pharms Usa Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
14/004 Ireland ➤ Sign Up PRODUCT NAME: TERIFLUNOMIDE, ITS STEREOISOMER AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/838/001-005 20130826
90006 Netherlands ➤ Sign Up PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAAT, EN HYDROCHLOORTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 - EU/1/98/086/006 19981015
1304992/01 Switzerland ➤ Sign Up PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
US Department of Justice
Cipla
Johnson and Johnson
Teva
Medtronic
Express Scripts
UBS
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.